SCHEMBL5803369

SCHEMBL5803369

CC(C)N(C)CC1CC(c2ccc(CN3CCCC3)cc2)C1

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 12/20 0.54
ALDH1A1 P00352 3/20 0.46
OPRM1 P35372 1/20 0.41
OPRK1 P41145 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
LSS P48449 1/20 0.40
NCF1 P14598 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5803366 1.00 HRH3 (0.54) HRH3ALDH1A1OPRM1OPRK1HRH4
SCHEMBL5791470 0.86 HRH3 (0.59) HRH3ALDH1A1HRH4KDM4EMEN1
SCHEMBL5785932 0.86 HRH3 (0.51) HRH3ALDH1A1HRH4KDM4EMEN1
SCHEMBL5785931 0.86 HRH3 (0.51) HRH3ALDH1A1HRH4KDM4EMEN1
SCHEMBL5802774 0.86 HRH3 (0.48) HRH3ALDH1A1OPRM1OPRK1MEN1
SCHEMBL5803209 0.86 HRH3 (0.48) HRH3ALDH1A1OPRM1OPRK1MEN1
SCHEMBL5802776 0.86 HRH3 (0.48) HRH3ALDH1A1OPRM1OPRK1MEN1
SCHEMBL5786733 0.85 HRH3 (0.52) HRH3ALDH1A1HRH4KDM4EMEN1
SCHEMBL5803200 0.85 HRH3 (0.52) HRH3ALDH1A1HRH4KDM4EMEN1
SCHEMBL5803199 0.85 HRH3 (0.52) HRH3ALDH1A1HRH4KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720847-A1 HISTAMINE-3 RECEPTOR MODULATORS Pfizer Products Incorporated (US) 2006-11-15 EP claimed
US-7115600-B2 Histamine-3 receptor modulators PFIZER INC. (US) 2006-10-03 US claimed
WO-2005080361-A1 HISTAMINE-3 RECEPTOR MODULATORS PFIZER PRODUCTS INC. (US) 2005-09-01 WO claimed
US-20050171181-A1 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker PFIZER INC 2005-08-04 US claimed
EP-1720847-A1 HISTAMINE-3 RECEPTOR MODULATORS Pfizer Products Incorporated (US) 2006-11-15 EP disclosed
US-7115600-B2 Histamine-3 receptor modulators PFIZER INC. (US) 2006-10-03 US disclosed
WO-2005080361-A1 HISTAMINE-3 RECEPTOR MODULATORS PFIZER PRODUCTS INC. (US) 2005-09-01 WO disclosed
US-20050171181-A1 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker PFIZER INC 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171181-A1 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker HRH3, HRH4, HRH1 HRH3 1/4885ALDH1A1 927/4885OPRM1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.